A cystic fibrosis patient homozygous for the nonsense mutation R553X

J Bal, M Stuhrmann, M Schloesser, J Schmidtke, J Reiss

Abstract
A cystic fibrosis patient homozygous for the nonsense mutation R553X was identified by mutation screening and the genotype confirmed by DNA sequencing. This patient, the only one described to date who is homozygous for this stop codon in exon 11 of the CFTR gene, is moderately severely affected. Clinical and molecular findings are presented.

Cystic fibrosis (CF) is the most frequent serious autosomal recessive disease in Caucasians, affecting approximately 1 in 2000 newborns. The gene is located on chromosome 7q31 and has been cloned and sequenced. The gene product is known as the 'cystic fibrosis transmembrane conductance regulator (CFTR)' and a structural model for this protein has been proposed. A large number of mutations in the CFTR gene associated with the CF phenotype have already been identified. It is, however, unclear if the highly variable clinical manifestation of CF is related to allelic heterogeneity or to other factors, either genetic or environmental. The most frequent mutation (ΔF508) is located in exon 10 of the CFTR gene and is found on approximately 70% of CF chromosomes. In general, ΔF508 is associated with severe CF.

Exons 9 to 12 are believed to encode the first of the two putative nucleotide binding folds. Cutting et al reported a cluster of mutations in exon 11, two of which, G551D and R553X, are frequently found in most populations. The R553X mutation substitutes an arginine codon for a stop codon, which would be expected to result in a severely truncated protein. So far, reports of three patients with homozygosity or compound heterozygosity for stop mutations have been published. Cuppens et al reported on a mildly affected patient who was homozygous for G542X and Cutting et al described two mildly affected patients with the genotypes W1316X/H553X and S1255X/G542X, respectively. We report here on a moderately severely affected patient who is homozygous for the nonsense mutation R553X.

Methods
One hundred and thirty-nine German cystic fibrosis patients with at least one non-ΔF508 allele were screened for mutations in exon 11 of the CFTR gene with restriction enzymes HincII and MboI. Seventeen of the total of 177 non-ΔF508 chromosomes exhibited the loss of a HincII site without the creation of a new MboI site. One patient was found to be homozygous for this type of deviation.

PCR amplified DNA of this patient encompassing the entire exon 11 was then directly sequenced on an automated fluorescence sequencer (Applied Biosystems, Foster City, model 373A) using protocols and labelled primers supplied by the vendor.

Case report
The proband was the first child born to healthy parents of German origin who are second degree relatives. His birth weight was 2950 g and length 52 cm. Failure to thrive was noted at the age of 16 months. He started to produce copious fatty stools and developed rectal prolapse.

Sweat tests were initially in the normal range, but soon became borderline and were clearly positive with 160 mEq/l sodium chloride at the age of 2 years 4 months. The patient suffered from a recurrent cough and developed pronounced pulmonary manifestations of CF with chronic obstructive bronchitis and peribronchitis. Staphylococcus aureus and Pseudomonas aeruginosa were found in his sputum from this age onwards. Lung function was only moderately affected when tested repeatedly between the ages of 11 and 13 years. Oral glucose tolerance was impaired at 11 years 9 months suggesting latent diabetes mellitus; stool chymotrypsin was then 11·1 U/g.

Institute of Human Genetics, Universität Göttingen, Gosslerstrasse 12d, D-3400 Göttingen, Germany. J Bal, M Schloesser, J Reiss

Department of Human Genetics, Medizinische Hochschule Hannover, Konstanty-Gutschow-Strasse 8, D-3000 Hannover 61, Germany. M Stuhrmann, J Schmidtke

Correspondence to Dr Reiss.

Received for publication 22 January 1991. Revised version accepted for publication 8 April 1991.
Pancreatic enzyme substitution therapy was started at 2 years 4 months of age. Whereas height was between the 25th and the 50th centile throughout the time period assessed (2 years 4 months to 13\(\frac{1}{2}\) years), his weight ranged only between well below the 3rd and the 10th centile. In view of this clinical picture, we tentatively classified this phenotype as moderately severe.

The sequence analysis of exon 11 of the patient is shown in the figure. Apart from the homozygous C1789GA to TGA alteration, no other deviation from the published wild type sequence was observed. Homozygosity for all RFLPs determined (table) and the consanguinity of the parents argue in favour of the two alleles being identical by descent.

**Discussion**

It is perhaps surprising that a nonsense mutation in the first half of the protein should have less dramatic effects than the absence of a single residue, as observed for the most common ΔF508 mutation. However, considerable evidence has already been published to support the hypothesis that in the absence of a functional allele, the total absence of the

```
AGAAATCTGCTCATTTGACCTCACAATCTCAGTG
```

Sequence analysis of the patient's exon 11. DNA was amplified with primers 11i-5' and 11i-3' in 40 cycles (1 min 92°C, 45 s 35°C, 2 min 63°C). 1 µl of this reaction was subjected to 25 cycles of asymmetrical PCR (30 s 94°C, 1 min 50°C, 2 min + 5 s extension per cycle 72°C) with 50 pmol primer 11i-5' and 15 pmol primer CF11RM (5'-TGTAATACGACGGCCAGTAAATGCTTTGCTAGACC), the latter containing an M13 primer binding site for single strand sequencing. Sequence analysis of the asymmetrical PCR product displays the reverse strand. The homozygous C1789GA to TGA substitution, indicated by the asterisk, results in a UGA stop codon.
CFTR protein is more likely to be compatible with certain cell or tissue requirements than the presence of an altered CFTR product in the cell membrane. A better understanding of this phenomenon might be obtained by studying the pattern of expression in the various tissues, especially in those rare patients who are homozygous for the described mutations. So far, no cell lines are available from our patient, but epithelial cells are currently being studied at the mRNA level.

The authors thank the patient and his family for cooperation, Drs Domagk (Göttingen) and Döhmen (Aachen) for providing clinical data, Bettina Pape for technical help, and David N Cooper for reading the manuscript. This study was supported by grants from the Deutsche Forschungsgemeinschaft and the Bundesministerium für Forschung und Technologie.

A cystic fibrosis patient homozygous for the nonsense mutation R553X.

J Bal, M Stuhrmann, M Schloesser, J Schmidtke and J Reiss

doi: 10.1136/jmg.28.10.715

Updated information and services can be found at:
http://jmg.bmj.com/content/28/10/715

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/